MedPath

Aggressive Intravenous Hydration With or Without Indometacin to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy

Not Applicable
Not yet recruiting
Conditions
Pancreatitis, Chronic
Pancreatitis, Acute
Pancreatic Duct Stones
Interventions
Drug: Indometacin suppository
Drug: Normal Saline
Registration Number
NCT07202559
Lead Sponsor
Changhai Hospital
Brief Summary

This study aims to determine whether combining aggressive intravenous hydration with indometacin is more effective at preventing pancreatitis after a Extracorporeal Shock Wave Lithotripsy (ESWL) than using indometacin alone.

The study will involve patients who are scheduled to undergo ESWL for pancreatic stones. Participants will be randomly assigned to one of two groups: one will receive both the intravenous hydration and the rectal indometacin, while the other will receive only the rectal indometacin.

The trial will be conducted at multiple centers, ensuring a broad and diverse patient population.

The primary outcome of the study will be the incidence of pancreatitis after the ESWL procedure.

This study is important because it could lead to a better understanding of how to prevent pancreatitis after ESWL, potentially improving patient outcomes and reducing the risk of serious complications.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
1250
Inclusion Criteria
  • Patients with painful chronic pancreatitis eligible for P-ESWL treatment
  • Ages between 18-85 years
  • Providing informed consent
Exclusion Criteria
  • Patients readmitted to the hospital for ESWL during the study period
  • contraindications to ESWL
  • Signs of congestive heart failure, such as pitting edema or a New York Heart Association classification greater than class I heart failure. For patients ≥ 70 years old, brain natriuretic peptide (BNP) and cardiac ultrasound would be performed before ESWL. Patients with BNP>100pg/ml or Ejection Fraction value<50% should be excluded
  • Respiratory insufficiency (pO2 < 60 mmHg or saturation < 90% despite FiO2 of 30% or requiring mechanical ventilation). For patients ≥ 70 years old, pulmonary function tests would be performed before ESWL. Patients with Forced Expiratory Volume in the first second (FEV1) <70% are excluded
  • Patients receiving more than 1.5 mL/kg/h or 3 L/24 h of intravenous fluids in the 24 h before ESWL
  • Hypotension (systolic blood pressure <90 mmHg or mean arterial pressure <70 mmHg)
  • Hypo- or hypernatremia (serum Na+ levels < 130 or > 150 mmol/L)
  • Severe liver disease (cirrhosis with ascites, liver abscess)
  • receiving NSAIDs within 7 days
  • Contraindications for rectal use of NSAIDs (renal dysfunction with serum creatinine >120 μmol/L, allergy, active gastrointestinal bleeding, ulcer disease, and NSAID use for other indications [other than cardioprotective aspirin])
  • presence of coagulopathy or received anticoagulation therapy within 3 days
  • acute pancreatitis within 3 days
  • known active cardiovascular or cerebrovascular disease
  • pregnant or breastfeeding women
  • without a rectum (ie, status post-total proctocolectomy)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Rectal indometacin aloneIndometacin suppositoryParticipants in this arm will receive a rectal administration of 100mg indometacin 30 minutes prior to ESWL. This group will not undergo aggressive hydration and will instead receive restricted hydration measures.
Rectal indometacin aloneNormal SalineParticipants in this arm will receive a rectal administration of 100mg indometacin 30 minutes prior to ESWL. This group will not undergo aggressive hydration and will instead receive restricted hydration measures.
Aggressive hydration with rectal IndometacinIndometacin suppositoryParticipants in this arm will also receive a rectal administration of 100mg indometacin 30 minutes before ESWL. In addition, they will undergo aggressive intravenous hydration using lactated Ringer's solution.
Aggressive hydration with rectal IndometacinLactated ringers solutionParticipants in this arm will also receive a rectal administration of 100mg indometacin 30 minutes before ESWL. In addition, they will undergo aggressive intravenous hydration using lactated Ringer's solution.
Primary Outcome Measures
NameTimeMethod
Incidence of post-ESWL pancreatitis24 hours

Post-ESWL pancreatitis is defined according to the 2012 Atlanta criteria. A diagnosis of post-ESWL pancreatitis is made if two of three of the following criteria are met: pain consistent with pancreatitis; amylase or lipase of at least three times the upper normal limit within 24 h of the procedure; or characteristic findings on imaging.

Secondary Outcome Measures
NameTimeMethod
Severity of pancreatitis1 month

Stratified as mild, moderate, or severe, mainly on the basis of length of hospitalization and need for invasive treatment.

Incidence of other post-ESWL complications24 hours

Including bleeding, infection, steinstrasse, and perforation.

Incidence of fluid overload24 hours

Including pulmonary or peripheral edema and congestive heart failure.

Transient adverse events related to ESWL24 hours

Transient adverse events were defined as transient injuries caused by shock waves that required no medical intervention and did not prolong hospitalisation, including asymptomatic hyperamylasaemia, haematuria, and acute gastrointestinal mucosal injury (eg, haematemesis, melena, or haem atochezia) caused by ESWL.

Asymptomatic hyper amylasaemia was defined as an increase in serum amylase compared with pre ESWL levels and beyond the upper limit of the normal range but showing no related symptoms.

Length of hospitalisation1 month

Trial Locations

Locations (10)

The Second Affiliated Hospital of Baotou Medical College

🇨🇳

Baotou, China

Peking Union Medical College Hospital

🇨🇳

Beijing, China

Hangzhou First People's Hospital

🇨🇳

Hangzhou, China

The Third Xiangya Hospital of Central South University

🇨🇳

Hunan, China

The First Hospital of Lanzhou University

🇨🇳

Lanzhou, China

Qilu Hospital of Shandong University

🇨🇳

Shandong, China

Changhai Hospital

🇨🇳

Shanghai, China

Ruijin Hospital

🇨🇳

Shanghai, China

Shanghai Pudong New Area Gongli Hospital

🇨🇳

Shanghai, China

Yunnan University Affiliated Hospital

🇨🇳

Yunnan, China

The Second Affiliated Hospital of Baotou Medical College
🇨🇳Baotou, China
Tong Dang
Contact
+8613948823999

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.